MacroGenics (MGNX) Earns “Buy” Rating from Raymond James Financial
MacroGenics (NASDAQ:MGNX)‘s stock had its “buy” rating restated by equities researchers at Raymond James Financial in a research report issued on Monday.
MGNX has been the subject of a number of other reports. Cowen reaffirmed a “buy” rating on shares of MacroGenics in a research note on Wednesday, October 25th. ValuEngine downgraded shares of MacroGenics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, November 14th. SunTrust Banks reaffirmed a “buy” rating and issued a $26.00 target price on shares of MacroGenics in a research note on Friday, September 1st. Zacks Investment Research cut shares of MacroGenics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. Finally, Citigroup lifted their price target on shares of MacroGenics from $18.00 to $22.00 and gave the stock a “neutral” rating in a research report on Friday, November 10th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $30.10.
MacroGenics (NASDAQ:MGNX) opened at $18.71 on Monday. MacroGenics has a 1-year low of $14.36 and a 1-year high of $27.00.
In related news, SVP Jon Marc Wigginton sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $20.00, for a total transaction of $100,000.00. Following the completion of the transaction, the senior vice president now owns 35,000 shares in the company, valued at $700,000. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 8.30% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of MGNX. Teacher Retirement System of Texas boosted its holdings in shares of MacroGenics by 13.8% in the second quarter. Teacher Retirement System of Texas now owns 3,848 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 466 shares during the period. Russell Investments Group Ltd. bought a new stake in shares of MacroGenics in the second quarter worth $133,000. Legal & General Group Plc lifted its position in shares of MacroGenics by 4.3% in the second quarter. Legal & General Group Plc now owns 7,925 shares of the biopharmaceutical company’s stock worth $138,000 after purchasing an additional 328 shares in the last quarter. BlackRock Group LTD lifted its position in shares of MacroGenics by 70.0% in the first quarter. BlackRock Group LTD now owns 8,944 shares of the biopharmaceutical company’s stock worth $168,000 after purchasing an additional 3,682 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of MacroGenics by 92.2% in the second quarter. SG Americas Securities LLC now owns 10,812 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 5,187 shares in the last quarter. Hedge funds and other institutional investors own 85.81% of the company’s stock.
MacroGenics Company Profile
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.